View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2016	Nov. 02, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Registrant Name	TAPIMMUNE INC
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	TPIV
Entity Common Stock, Shares Outstanding		8,379,101

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current Assets
Cash	$ 9,586,773	$ 6,576,564
Prepaid expenses and deposits	111,652	68,803
Total Assets	9,698,425	6,645,367
Current Liabilities
Accounts payable and accrued liabilities	1,678,079	967,358
Research agreement obligations	492,365	492,365
Derivative liability - warrants	29,000	26,493,000
Promissory note	5,000	30,000
Promissory note, related party	0	23,000
Total Liabilities	2,204,444	28,005,723
Commitments and Contingencies
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized
Common stock, $0.001 par value, 41,666,667 shares authorized, 8,395,768 and 5,882,976 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	8,396	5,884
Additional paid-in capital	151,724,573	112,142,187
Accumulated deficit	(144,238,988)	(133,508,427)
Total Stockholders’ Equity (Deficit)	7,493,981	(21,360,356)
Total Liabilities and Stockholders’ Equity (Deficit)	9,698,425	6,645,367
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized	0	0
Series B Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	41,666,667	41,666,667
Common stock shares issued	8,395,768	5,882,976
Common stock shares outstanding	8,395,768	5,882,976
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating Expenses:
Research and development	$ 1,109,332	$ 968,759	$ 3,343,248	$ 2,324,432
General and administrative	1,612,305	769,219	3,557,701	1,579,754
Loss from Operations	(2,721,637)	(1,737,978)	(6,900,949)	(3,904,186)
Other Income (Expense)
Changes in fair value of derivative liabilities	684,000	30,266,000	5,925,000	(28,485,585)
Foreign exchange gain	0	0	0	775
Grant income	0	0	231,200	0
Loss on debt settlement agreements	(65,325)	(24,697)	(135,640)	(24,697)
Other income	0	0	1,828	0
Net Income (Loss)	$ (2,102,962)	$ 28,503,325	$ (878,561)	$ (32,413,693)
Basic Net Income (Loss) per Share	$ (0.29)	$ 7.04	$ (0.14)	$ (10.61)
Diluted Net Income (Loss) per Share	$ (0.29)	$ 4.23	$ (0.54)	$ (10.61)
Weighted Average Number of Common Shares Outstanding, Basic	7,281,000	4,048,750	6,370,000	3,054,297
Weighted Average Number of Common Shares Outstanding, diluted	7,281,000	6,745,416	6,935,000	3,054,297

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 9 months ended Sep. 30, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance, Amount at Dec. 31, 2015	$ (21,360,356)	$ 5,884	$ 112,142,187	$ (133,508,427)
Beginning Balance, Share at Dec. 31, 2015		5,882,976
Issuance of common stock in private placement (in shares)		653,166
Issuance of common stock in private placement	3,135,196	$ 653	3,134,543	0
Finders’ fee and legal costs relating to private placements	(804,070)	0	(804,070)	0
Fair value of shares issued as inducement on August 10, 2016	0	$ 750	4,499,250	(4,500,000)
Fair value of shares issued as inducement on August 10, 2016 (in shares)		750,000
Fair value of series F and F-1 warrants issued as inducement in August 2016	0	$ 0	5,352,000	(5,352,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	15,465,000	0	15,465,000	0
Exercise of warrants Amount	6,000,000	$ 1,000	5,999,000	0
Exercise of warrants share		1,000,000
Finders’ fee on exercise of warrants	(516,651)	$ 0	(516,651)	0
Reclassification of fair value of derivative liabilities at exercise date	5,074,000	0	5,074,000	0
Shares issued in debt settlement agreements	70,315	$ 10	70,305	0
Shares issued in debt settlement agreements, Shares		10,191
Stock- based compensation, Amount	1,309,108	$ 99	1,309,009	0
Stock- based compensation, Share		99,435
Net loss	(878,561)	$ 0	0	(878,561)
Ending Balance, Amount at Sep. 30, 2016	$ 7,493,981	$ 8,396	$ 151,724,573	$ (144,238,988)
Ending Balance, Share at Sep. 30, 2016		8,395,768

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flow from operating activities
Net loss	$ (878,561)	$ (32,413,693)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	(5,925,000)	28,485,585
Loss on debt settlement agreements	70,315	24,697
Stock based compensation	1,309,109	261,805
Changes in operating assets and liabilities:
Prepaid expenses	(42,849)	(55,782)
Accounts payable and accrued liabilities	710,720	204,956
Net cash used in operating activities	(4,756,266)	(3,492,432)
Cash flow from financing activities
Private placements	3,135,196	2,464,000
Finders’ fee and legal costs on private placements	(804,070)	(137,986)
Repayment of promissory note	(25,000)	0
Repayment of promissory note - related party	(23,000)	0
Proceeds from exercise of warrants	6,000,000	7,427,998
Finders' fee on exercise of warrants	(516,651)	(316,508)
Net cash provided by financing activities	7,766,475	9,437,504
Net increase in cash	3,010,209	5,945,072
Cash, beginning of period	6,576,564	141,944
Cash, end of period	9,586,773	6,087,016
Supplemental disclosure of cash flow information
Cash paid for interest	0	0
Cash paid for taxes	0	0
Supplemental schedule of non-cash investing and financing activities:
Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson's compensation	191,000	0
Accounts payable settled in common stock	0	24,000
Fair value of issuance of series F and F-1 warrants as inducement in August 2016	5,352,000	0
Fair value of shares issued as inducement on August 10, 2016	4,500,000	0
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	15,465,000	0
Fair value of issuance of warrants in January and March 2015 financing	0	9,313,000
Issuance of additional warrants in May 28, 2015 transaction	0	6,133,000
Reclassification of Derivative Warrant Liabilities to Equity at Exercise Date	$ 5,074,000	$ 11,745,000

NATURE OF OPERATIONS

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

Note 1:

Nature of Operations

TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

BASIS OF PRESENTATION

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

NOTE 2:

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.

The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2016 or for any future interim period. The condensed consolidated balance sheet at December 31, 2015 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2015, and notes thereto included in the Company’s annual report on Form 10-K.

LIQUIDITY AND FINANCIAL CONDITION

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

LIQUIDITY AND FINANCIAL CONDITION

NOTE 3:

LIQUIDITY AND FINANCIAL CONDITION

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

As of September 30, 2016, the Company had cash and cash equivalents of approximately $9,587,000. Historically, the Company had net losses and negative cash flows from operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Note 4:

SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2016 other than the one disclosed below relating to grant income:

Grant Income

The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company’s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as grant income when received.

Recent Accounting Pronouncement

Accounting Standards Update (“ASU”), No. 2016-09 - In March 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-09, Compensation-Stock Compensation. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the specific changes associated with the update include all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) being recognized as income tax expense or benefit in the income statement. The tax effects of exercised or vested awards should be treated as discrete items in the reporting period in which they occur. An entity also should recognize excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. An entity can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years.

The Company has evaluated the impact of ASU No. 2016-09 and has determined that the adoption of the impact of forfeitures, net of income taxes, will not have a material impact on the Company’s future financial statements.

NET INCOME (LOSS) PER SHARE

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

NET INCOME (LOSS) PER SHARE

Note 5:

net income (loss) per share

Basic income (loss) per common share is computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted income per common share is computed similar to basic income per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

Income (loss) per-share amounts for all periods have been retroactively adjusted to reflect the Company’s 1-for-12 reverse stock split, which was effective September 16, 2016.

The following table sets forth the computation of income (loss) per share:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2016		2015		2016		2015

Net income (loss)	$	(2,102,962)	$	28,503,325	$	(878,561)	$	(32,413,693)
Less: Non cash income from changes in fair value of derivative liabilities		-		-		(2,856,000)		-
Net income (loss) - diluted		(2,102,962)		28,503,325		(3,734,561)		(32,413,693)

Weighted average shares outstanding - basic		7,281,000		4,048,750		6,370,000		3,054,297
Common stock warrants		-		2,663,333		565,000		-
Common stock options		-		33,333		-		-
Weighted average shares outstanding - diluted		7,281,000		6,745,416		6,935,000		3,054,297

Net income (loss) per share data:
Basic	$	(0.29)	$	7.04	$	(0.14)	$	(10.61)
Diluted	$	(0.29)	$	4.23	$	(0.54)	$	(10.61)

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Nine Months Ended September 30,
	2016		2015
Common stock options		432,000		39,000
Common stock warrants - equity treatment		5,054,000		211,000
Common stock warrants - liability treatment		6,000		4,750,000
Potentially dilutive securities		5,492,000		5,000,000

DERIVATIVE LIABILITY - WARRANTS

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

DERIVATIVE LIABILITY - WARRANTS

Note 6:

DERIVATIVE LIABILITY - WARRANTs

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended 2016 and 2015 is as follows:

Share Purchase Warrants	Weighted Average Inputs for the Period
	For the Nine			For the Nine
	Months Ending			Months Ending
	September 30,			September 30,
Date of valuation	2016			2015
Exercise price	$	1.20		$	7.56
Contractual term (years)		1.3			4.5
Volatility (annual)		105	%		159	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

⋅

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

⋅

Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and

⋅

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

	As of September 30, 2016
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	29,000		-		-	$	29,000	$	29,000
Total	$	29,000		-		-	$	29,000	$	29,000

	As of December 31, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	26,493,000		-		-	$	26,493,000	$	26,493,000
Total	$	26,493,000		-		-	$	26,493,000	$	26,493,000

There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2016.

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2016:

	Derivative liability – warrants
Balance – December 31, 2015	$	26,493,000
Reclassification of derivative liabilities to equity at exercise date		(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		(15,465,000)
Change in fair value of warrant liability		(5,925,000)
Balance – September 30, 2016	$	29,000

Warrant Amendment Transaction

On August 10, 2016, the Company and holders of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements (the “Amended Warrants”) in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity classification treatment on the Company’s balance sheets.

In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of 750,000 additional shares of common stock to such warrant holders and new five-year warrants to purchase 1,000,000 shares of Company common stock at an exercise price of $7.20 per share. The value of the shares and fair value of the warrants was treated as dividend on the statement of stockholders’ equity of $4.5 million.

The fair value of the Amended Warrants was re-measured immediately prior to the date of amendment with changes in fair value recorded as a gain of $556,000 in the statement of operations and $15.5 million was reclassified to equity.

STOCK-BASED COMPENSATION

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Note 7:

STOCK-BASED COMPENSATION

The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015, respectively:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	-	$	-	$	-	$	-
General and administrative		573,137		13,244		1,309,109		261,805

Total stock-based compensation	$	573,137	$	13,244	$	1,309,109	$	261,805

Stock Options

A summary of the Company’s stock option activity is as follows:


			Weighted Average		Weighted Average
			Exercise Price		Remaining		Aggregate
	Stock Options		per Share		Contractual Life		Intrinsic Value

Outstanding as of December 31, 2015		298,679	$	9.25		9.75	$	177,000

Granted		135,000		6.00
Exercised		-		-
Forfeited/Cancelled		(1,667)		228.00

Outstanding as of September 30, 2016		432,013	$	7.25		9.25	$	271,000

Exercisable as of September 30, 2016		262,395	$	8.00		9.00	$	174,000

Total stock-based compensation cost related to unvested awards not yet recognized and the weighted average periods over which the awards are expected to be recognized as of September 30, 2016 are as follows:

Unrecognized stock-based compensation cost:		$	1,081,000
Expected weighted average period compensation costs to be recognized (years):			1.75

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

PROMISSORY NOTE

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

PROMISSORY NOTE

Note 8: Promissory note

At September 30, 2016, the Company had an outstanding promissory note in the amount of $5,000 as compared to two outstanding promissory notes totaling $30,000 at December 31, 2015. The promissory note outstanding at September 30, 2016 bears 10% annual interest.

During the nine months ended September 30, 2016, the Company paid a $25,000 promissory note and $6,524 of accrued interest in final settlement.

PROMISSORY NOTE, RELATED PARTY

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

PROMISSORY NOTE, RELATED PARTY

Note 9: Promissory note, related party

At December 31, 2015, the Company had an outstanding promissory note in the amount of $23,000 owed to an officer of the Company. The promissory note bore no interest charges and had no fixed repayment terms. In September 2016, the note was paid in full.

CAPITAL STOCK

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

CAPITAL STOCK

Note 10: Capital Stock

Reverse Stock Split

Effective September 16, 2016, the Company effected a one for twelve reverse stock-split of our issued and outstanding common stock and has retroactively adjusted our common shares outstanding, options and warrants amounts outstanding. The Company has presented its share data for and as of all periods presented on this basis. The par value was not adjusted as a result of the one for twelve reverse stock split. All prior period share transactions included in the Company’s stock transactions and balances have been retroactively restated.

2016 Common Stock Transactions

Private placements

On August 10, 2016 and August 25, 2016, the Company completed private placements of units with certain accredited investors. The units consisted of (i) one share of the Company’s common stock, par value $0.001 per share and (ii) one five-year warrant to purchase one share of Company common stock for $6.00. The Company issued and sold an aggregate of 653,166 units at a purchase price per unit of $4.80 for an aggregate of approximately $3.1 million. The Company incurred approximately $0.8 million in agency fees and legal costs.

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80 per share.

Pursuant to the registration rights agreements entered into in connection with the private placements, the Company is required to file a registration statement with the Securities and Exchange Commission registering for resale (a) the common stock issued in the private placement offering; (b) the shares of common stock issuable upon the exercise of the five-year warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to the placement agent. The Company is required to file the registration statement within 120 days of the August 10, 2016 closing or by December 8, 2016. The Company is also required to ensure that the registration statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission, or by March 8, 2017.

In accordance with the registration rights agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages. The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (10%) per annum of the aggregate purchase price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.

In accordance with applicable U.S. generally accepted accounting principles, a contingent obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be required to record would be approximately $29,000 per month for each month it fails or is estimated to fail to meet the above criteria.

At the August 10, 2016 and August 26,2016 private placement closings, and on September 30, 2016, the Company concluded that it is not probable that it will be required to remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.

Warrant Amendment Transaction

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of September 30, 2016 and changes during the period is presented below:

	Number of Warrants		Weighted Average Exercise Price
Balance, December 31, 2015		4,343,000	$	8.67
Exercised		(1,000,000)		6.00
Issued		1,718,000		6.65
Expired		(2,000)		300
Balance, September 30, 2016		5,059,000	$	8.51

Consulting Arangements

During the nine months ended September 30, 2016, the Company issued 60,000 common shares as part of consulting agreements. The fair value of the common stock of approximately $414,000 was recognized as stock-based compensation in general and administrative expense.

Debt Settlement

In May 2016, the Company issued 10,191 common shares as part of debt conversion agreements from 2014. The fair value of the common stock of approximately $70,000 was recognized as loss on debt settlement agreements in other income (expense).

In September 2016, the Company paid $27,000 for a promissory note from 2008 and related $38,000 of accrued interest. The $65,000 payment was recognized as loss on debt settlement agreements in other income (expense).

GRANT INCOME

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

GRANT INCOME

Note 11: grant income

During the nine months ended September 30, 2016, the Company received approximately $231,000 of grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV 200. The grant paid for the clinical supplies purchased by the Company.

COMMITMENTS

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS

Note 12:

COMMITMENTS

Employment Agreements

In November 2015, the Company entered into an employment agreement with Dr. Glynn Wilson, the Company’s Chief Executive Officer, President and Chairman of the Company. As part of the agreement, Dr. Wilson was awarded 19,018 fully vested common shares in March 2016. The fair value of the common stock of approximately $146,000 was recognized as stock-based compensation in general and administrative expense.

In July, 2016, the Company entered into an employment agreement with Dr. John Bonfiglio relating to his appointment as the Company’s President and Chief Operating Officer. As part of the agreement, Dr. Bonfiglio was awarded 20,833 common shares, which will vest upon the earlier of (i) the listing of the Company’s common stock on a national securities exchange in the United States or (ii) the first anniversary of the employment agreement, so long as Dr. Bonfiglio is employed with the Company. The fair value of the common stock of approximately $103,000 was recognized as stock-based compensation in general and administrative expense.

In August 2016, the Company appointed Michael Loiacono as the Company’s Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer. In connection with Mr. Loiacono’s appointment he entered into an employment agreement with the Company. The employment agreement provides that Mr. Loiacono’s base salary will be $200,000 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. The term of the employment agreement is for two years and will be automatically extended for an additional 12 months unless terminated by Mr. Loiacono or the Company.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Grant Income

Grant Income

Recent accounting pronouncement

Recent Accounting Pronouncement

NET INCOME (LOSS) PER SHARE (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Computation Of Income Loss Per Share

The following table sets forth the computation of income (loss) per share:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2016		2015		2016		2015

Net income (loss)	$	(2,102,962)	$	28,503,325	$	(878,561)	$	(32,413,693)
Less: Non cash income from changes in fair value of derivative liabilities		-		-		(2,856,000)		-
Net income (loss) - diluted		(2,102,962)		28,503,325		(3,734,561)		(32,413,693)

Weighted average shares outstanding - basic		7,281,000		4,048,750		6,370,000		3,054,297
Common stock warrants		-		2,663,333		565,000		-
Common stock options		-		33,333		-		-
Weighted average shares outstanding - diluted		7,281,000		6,745,416		6,935,000		3,054,297

Net income (loss) per share data:
Basic	$	(0.29)	$	7.04	$	(0.14)	$	(10.61)
Diluted	$	(0.29)	$	4.23	$	(0.54)	$	(10.61)

Net Loss Per Share

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Nine Months Ended September 30,
	2016		2015
Common stock options		432,000		39,000
Common stock warrants - equity treatment		5,054,000		211,000
Common stock warrants - liability treatment		6,000		4,750,000
Potentially dilutive securities		5,492,000		5,000,000

DERIVATIVE LIABILITY - WARRANTS (Tables)

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

Valuation Methodology

Share Purchase Warrants	Weighted Average Inputs for the Period
	For the Nine			For the Nine
	Months Ending			Months Ending
	September 30,			September 30,
Date of valuation	2016			2015
Exercise price	$	1.20		$	7.56
Contractual term (years)		1.3			4.5
Volatility (annual)		105	%		159	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

	As of September 30, 2016
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	29,000		-		-	$	29,000	$	29,000
Total	$	29,000		-		-	$	29,000	$	29,000

	As of December 31, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	26,493,000		-		-	$	26,493,000	$	26,493,000
Total	$	26,493,000		-		-	$	26,493,000	$	26,493,000

Schedule of Changes in Level 3 Liabilities Measured at Fair Value

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2016:

	Derivative liability – warrants
Balance – December 31, 2015	$	26,493,000
Reclassification of derivative liabilities to equity at exercise date		(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		(15,465,000)
Change in fair value of warrant liability		(5,925,000)
Balance – September 30, 2016	$	29,000

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	-	$	-	$	-	$	-
General and administrative		573,137		13,244		1,309,109		261,805

Total stock-based compensation	$	573,137	$	13,244	$	1,309,109	$	261,805

Schedule of Share-based Compensation, Activity

A summary of the Company’s stock option activity is as follows:


			Weighted Average		Weighted Average
			Exercise Price		Remaining		Aggregate
	Stock Options		per Share		Contractual Life		Intrinsic Value

Outstanding as of December 31, 2015		298,679	$	9.25		9.75	$	177,000

Granted		135,000		6.00
Exercised		-		-
Forfeited/Cancelled		(1,667)		228.00

Outstanding as of September 30, 2016		432,013	$	7.25		9.25	$	271,000

Exercisable as of September 30, 2016		262,395	$	8.00		9.00	$	174,000

Schedule of Unrecognized Compensation Cost, Nonvested Awards

Unrecognized stock-based compensation cost:		$	1,081,000
Expected weighted average period compensation costs to be recognized (years):			1.75

CAPITAL STOCK (Tables)

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

Capital Stock

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of September 30, 2016 and changes during the period is presented below:

	Number of Warrants		Weighted Average Exercise Price
Balance, December 31, 2015		4,343,000	$	8.67
Exercised		(1,000,000)		6.00
Issued		1,718,000		6.65
Expired		(2,000)		300
Balance, September 30, 2016		5,059,000	$	8.51

LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail)	Sep. 30, 2016 USD ($)
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 9,587,000

NET INCOME (LOSS) PER SHARE - Computation of income (loss) per share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net income (loss)	$ (2,102,962)	$ 28,503,325	$ (878,561)	$ (32,413,693)
Less: Non cash income from changes in fair value of derivative liabilities	0	0	(2,856,000)	0
Net income (loss) - diluted	$ (2,102,962)	$ 28,503,325	$ (3,734,561)	$ (32,413,693)
Weighted average shares outstanding - basic	7,281,000	4,048,750	6,370,000	3,054,297
Common stock warrants	0	2,663,333	565,000	0
Common stock options	0	33,333	0	0
Weighted average shares outstanding - diluted	7,281,000	6,745,416	6,935,000	3,054,297
Net income (loss) per share data:
Basic	$ (0.29)	$ 7.04	$ (0.14)	$ (10.61)
Diluted	$ (0.29)	$ 4.23	$ (0.54)	$ (10.61)

NET INCOME (LOSS) PER SHARE - Potentially Dilutive Securities (Detail) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Common stock options	432,000	39,000
Common stock warrants - equity treatment	5,054,000	211,000
Common stock warrants - liability treatment	6,000	4,750,000
Potentially dilutive securities	5,492,000	5,000,000

NET INCOME (LOSS) PER SHARE - Additional Information (Detail)	1 Months Ended
	Sep. 30, 2016
Stockholders' Equity, Reverse Stock Split	1-for-12

DERIVATIVE LIABILITY - WARRANTS - Additional Information (Detail) - USD ($)		1 Months Ended
	Aug. 10, 2016	Sep. 30, 2016	Dec. 31, 2015
Class of Warrant or Right, Outstanding	3,096,665	5,059,000	4,343,000
Stock Issued During Period Shares, Upon Exercise Of Warrants	750,000
Class Of Warrant Or Right Expiration Period	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.20
Derivative, Gain on Derivative		$ 556,000
Fair Value Of Warrant Reclassification To Equity		$ 15,500,000
Dividends	$ 4,500,000

DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 1.20	$ 7.56
Contractual term (years)	1 year 3 months 18 days	4 years 6 months
Volatility (annual)	105.00%	159.00%
Risk-free rate	1.00%	1.00%
Dividend yield (per share)	0.00%	0.00%

DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	$ 29,000	$ 26,493,000
Total	29,000	26,493,000
Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	29,000	26,493,000
Total	29,000	26,493,000
Fair Value [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	29,000	26,493,000
Total	$ 29,000	$ 26,493,000

DERIVATIVE LIABILITY - WARRANTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)	9 Months Ended
	Sep. 30, 2016 USD ($)
Balance - December 31, 2015	$ 26,493,000
Reclassification of derivative liabilities to equity at exercise date	(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	(15,465,000)
Change in fair value of warrant liability	(5,925,000)
Balance - September 30, 2016	$ 29,000

STOCK-BASED COMPENSATION - Components of Stock-based Compensation Expense (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Allocated Share-based Compensation Expense	$ 573,137	$ 13,244	$ 1,309,109	$ 261,805
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	0	0	0	0
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	$ 573,137	$ 13,244	$ 1,309,109	$ 261,805

STOCK-BASED COMPENSATION - Stock Option Activity (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Stock Options Outstanding, Begining Balance	298,679
Stock Options, Granted	135,000
Stock Options, Exercised	0
Stock Options, Forfeited/Cancelled	(1,667)
Stock Options Outstanding, Ending Balance	432,013	298,679
Stock Options, Exercisable as of September 30, 2016	262,395
Weighted Average Exercise Price per Share Outstanding, Begining Balance		$ 9.25
Weighted Average Exercise Price per Share, Granted	$ 6.00
Weighted Average Exercise Price per Share, Exercised	0
Weighted Average Exercise Price per Share, Forfeited/Cancelled	228.00
Weighted Average Exercise Price per Share Outstanding, Ending Balance	7.25
Weighted Average Exercise Price per Share Exercisable as of September 30, 2016	$ 8.00
Weighted Average Remaining Contractual Life, Outstanding	9 years 3 months	9 years 9 months
Weighted Average Remaining Contractual Life, Exercisable as of September 30, 2016	9 years
Aggregate Intrinsic Value Outstanding	$ 271,000	$ 177,000
Aggregate Intrinsic Value, Exercisable as of September 30, 2016	$ 174,000

STOCK-BASED COMPENSATION - Cost Related to Unvested Awards Not Yet Recognized and the Weighted Average Periods (Detail)	9 Months Ended
	Sep. 30, 2016 USD ($)
Unrecognized stock-based compensation cost:	$ 1,081,000
Expected weighted average period compensation costs to be recognized (years):	1 year 9 months

PROMISSORY NOTE - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Outstanding promissory notes	$ 5,000	$ 30,000
Repayments of Notes Payable	25,000
Debt Instrument Repayments of Accured Interest	$ 6,524
Promissory Notes Due in 2012 [Member]
Debt Instrument [Line Items]
Annual interest rate	10.00%

PROMISSORY NOTE, RELATED PARTY - Additional Information (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Outstanding promissory notes	$ 0	$ 23,000

CAPITAL STOCK - Share Purchase Warrants (Detail)	9 Months Ended
CAPITAL STOCK - Share Purchase Warrants (Detail)	Sep. 30, 2016 $ / shares shares
Number of Warrants, Beginning balance \| shares	4,343,000
Number of Warrants, Exercised \| shares	(1,000,000)
Number of Warrants, Issued \| shares	1,718,000
Number of Warrants, Expired \| shares	(2,000)
Number of Warrants, Ending balance \| shares	5,059,000
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 8.67
Weighted Average Exercise Price, Exercised \| $ / shares	6.00
Weighted Average Exercise Price, Issued \| $ / shares	6.65
Weighted Average Exercise Price, Expired \| $ / shares	300
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 8.51

CAPITAL STOCK - Additional Information (Detail)		1 Months Ended			3 Months Ended		9 Months Ended
CAPITAL STOCK - Additional Information (Detail)	Aug. 10, 2016 USD ($) $ / shares shares	Sep. 16, 2016	Aug. 31, 2016 USD ($) $ / shares $ / Unit shares	May 31, 2016 USD ($) shares	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($) $ / shares shares
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.001		$ 0.001		$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 7.20
Class Of Warrant Or Right Expiration Period	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000
Stockholders' Equity Note, Stock Split, Conversion Ratio		12
Class of Warrant or Right, Warrant Terms							5 years
Payment Of Liquidated Damages, Percentages							10.00%
Derivative Liability, Current \| $					$ 29,000		$ 29,000		$ 26,493,000
Repayments of Notes Payable \| $							25,000
Gain (Loss) on Extinguishment of Debt \| $					$ (65,325)	$ (24,697)	$ (135,640)	$ (24,697)
Class of Warrant or Right, Outstanding	3,096,665				5,059,000		5,059,000		4,343,000
Commercial Paper [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Debt Instrument, Periodic Payment, Interest \| $							$ 38,000
Amended Warrants [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 7.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000
Class Of Warrant Or Right Warrant Term	5 years
Class of Warrant or Right, Outstanding	3,096,665
Stock Issued During Period, Shares, New Issues	750,000
Fair Value Adjustment of Warrants \| $	$ 4,500,000
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 6.00
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Class Of Warrant Or Right Expiration Period			5 years
Legal Fees \| $			$ 800,000
Number of common stocks included in unit offering			1
Number Of Equity Unit Issued			653,166
Equity Unit Issued Price Per Unit \| $ / Unit			4.80
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement \| $			$ 3,100,000
Consulting Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $							$ 414,000
Common shares issued							60,000
Debt Conversion Agreement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $				$ 70,000
Common shares issued				10,191
Placement Agent [Member] \| Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 4.80
Class Of Warrant Or Right Expiration Period			5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			65,317

GRANT INCOME - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue from Grants	$ 0	$ 0	$ 231,200	$ 0

COMMITMENTS - Additional Information (Detail) - USD ($)	1 Months Ended			9 Months Ended
COMMITMENTS - Additional Information (Detail) - USD ($)	Aug. 31, 2016	Jul. 31, 2016	Mar. 31, 2016	Sep. 30, 2016	Sep. 30, 2015
Commitments And Contingencies [Line Items]
Annual Performance Bonus On Base Salary, Percentage	50.00%
Salaries, Wages and Officers' Compensation	$ 200,000
Share-based Compensation				$ 1,309,109	$ 261,805
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				135,000
Chief Executive Officer, President and Chairman [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			19,018
Chief Executive Officer, President and Chairman [Member] \| General and Administrative Expense [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation			$ 146,000
Chief Operating Officer [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		20,833
Chief Operating Officer [Member] \| General and Administrative Expense [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation		$ 103,000